Here we provide links to some of the key peer-reviewed publications behind the discovery and development of our immunotherapy technologies for glioblastoma multiforme (GBM) and other solid tumor cancers.

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity  Nature Communications January 2020

Recurrent glioblastoma treated with recombinant poliovirus New England Journal of Medicine, June 2018.

When viruses attack – Nature Reviews: Cancer, October 2017.

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs – Science Translational Medicine, Sept. 2017.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models- Oncotarget, Oct. 2016.

Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus – Discovery Medicine, May 2015.

Induction of viral, 7-methyl-guanosine Cap-Independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase – Journal of Virology, Nov 2014.

Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis – Journal of Virology, March 2012.

Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype – Molecular Therapy, Nov 2008.

Intergeneric poliovirus recombinants for the treatment of malignant glioma – PNAS, June 2000.